Evidence map›Paper›PMID 42517280›Full record

ArticleReproduction & fertility2026

Clinical validity of Midway PGT-A: a comparative study with traditional PGT-A and analysis of fertilization strategies.

Jiujie Dou, Zhan Hu, Boya Zhao, Senlin Shi

Abstract readComparative Study
In one paragraph

Article in Reproduction & fertility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiujie DouCenter for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China.
Zhan HuCenter for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China.
Boya ZhaoCenter for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China.
Senlin ShiCenter for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China.ORCID 0000-0002-4814-1510

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

graphical abstractABSTRACT: Infertile patients initially undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) with fresh embryo transfer often lack baseline indications for preimplantation genetic testing for aneuploidy (PGT-A); however, after multiple failed transfers, they may become eligible for PGT-A, which can be performed on residual vitrified-thawed embryos (a strategy termed 'Midway PGT-A'), whose clinical value remains unconfirmed. This study aimed to assess the clinical utility of Midway PGT-A and whether fertilization methods (IVF vs ICSI) affect its chromosomal testing results and clinical outcomes. A 2020-2023 retrospective cohort study analyzed 463 PGT-A cycles, comprising 202 Midway PGT-A cycles (132 IVF and 70 ICSI subcycles) and 261 traditional PGT-A cycles, with comparisons made regarding blastocyst aneuploidy profiles and clinical pregnancy outcomes. The results showed that compared with traditional PGT-A, Midway PGT-A was associated with fewer biopsied blastocysts (P < 0.05), a higher rate of numerical chromosomal abnormalities (P < 0.05), and a lower rate of structural chromosomal abnormalities (P < 0.05). In the Midway PGT-A group, IVF and ICSI subcycles had similar euploidy and aneuploidy rates, but the IVF subcycle exhibited a significantly higher clinical pregnancy rate (P < 0.05) and implantation rate (P < 0.05). Multivariable logistic regression confirmed that ICSI was independently associated with a lower clinical pregnancy rate compared with IVF. In summary, Midway PGT-A delivers equivalent outcomes compared with traditional PGT-A. IVF does not alter the chromosomal detection results of Midway PGT-A and may further optimize clinical reproductive performance, validating the clinical value of Midway PGT-A for patients with post-transfer PGT-A eligibility. LAY SUMMARY: Many people undergoing fertility treatments do not need embryo genetic testing initially. However, after repeated failed pregnancies, miscarriages, or having a baby with birth defects, they may need this test later. We tested the genetic health of their leftover frozen embryos - a strategy we call 'Midway testing'. Our study of 463 cycles found that Midway testing worked as well as standard testing done earlier. The number of embryos tested was lower for Midway testing, but it found more whole-chromosome issues and fewer chromosome structure issues. Fertilization methods did not change test results, but one method led to higher pregnancy and implantation rates. This testing offers a valuable option for people who need genetic embryo checks after failed fertility cycles, helping them use existing frozen embryos effectively.

Indexed as

AneuploidyFertilization in VitroGenetic TestingPreimplantation DiagnosisAdultCryopreservationEmbryo TransferFemaleHumansPregnancyPregnancy OutcomePregnancy RateRetrospective StudiesSperm Injections, Intracytoplasmicclinical outcomesdouble vitrificationeuploidyMidway PGT-Atraditional PGT-A

Identifiers

PMID42517280
PMCPMC13482791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.